ROIV News and Press, Roivant Sciences Ltd. From 03/16/23

2023-03-16 17:24:42 ET Gainers: Hub Cyber Security ( HUBC ) +6% . Altimmune ( ALT ) +5% . Hawaiian Holdings ( HA ) +4% . MacroGenics ( MGNX ) +3% . PENN Entertainment ( PENN ) +3% . Losers: Sarepta Therapeutics ( NASDAQ...

46.4% of subjects receiving VTAMA cream, 1% achieved the primary endpoint of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD TM ) response of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at Week 8, versus 18.0% on vehicle (P<0.0001...

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Wednesday, March 15 to review topline results from the ADORING 2 study, one of two replicat...

NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Proteovant Therapeutics , a Roivant Sciences (Nasdaq: ROIV) company leveraging the process of protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases, today announced ...

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences (Nasdaq: ROIV), today announced the formation of its Scientific Advisory Board (SAB). Covant uses its unprecedented high-throughput chemoproteomics platform ...

2023-03-06 14:38:37 ET Summary In its recent past, Roivant has successfully generated a series of satellite companies it calls Vants; it monetized part of its portfolio in 2019. More recently, Roivant went public and listed its shares on NASDAQ. Roivant's one approved therapy ...

Summary The stock of Prometheus Biosciences has tripled since positive mid-stage trial results for its primary candidate for treating UC and CD came out in early December. Since then the company has done a large capital raise and there have been some significant insider sales so far in ...

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its founder Vivek Ramaswamy has stepped down from the company’s board of directors to focus on his U.S. presidential campaign. Vivek founded R...

Vivek Ramaswamy, the founder and former CEO of Roivant Sciences ( NASDAQ: ROIV ), is considering a bid for the Republican presidential nomination, POLITICO reported. The political news website said that the former exec, who is also known for launching several other "vant" companies, s...

Roivant Sciences press release ( NASDAQ: ROIV ): Q3 GAAP EPS of -$0.49 misses by $0.09 . Revenue of $17.05M (-30.0% Y/Y) beats by $2.27M . $9.2M in net product revenue from VTAMA reported for the quarter ended December 31, 2022, with nearly 100,000 VTAMA prescriptions ...